Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies

被引：129

作者：

Anitua, Eduardo ^{[1
]}

Muruzabal, Francisco ^{[1
]}

Tayebba, Ali ^{[2
]}

Riestra, Ana ^{[3
]}

Perez, Victor L. ^{[2
]}

Merayo-Lloves, Jesus ^{[3
]}

Orive, Gorka ^{[1
]}

机构：

[1] BTI Biotechnol Inst, Vitoria 01007, Alava, Spain

[2] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst,Ocular Surface Ctr, Microbiol & Immunol,Walter G Ross Chair Ophthalm, Miami, FL 33136 USA

[3] Univ Oviedo, Eye Res Fdn, Fernandez Vega Ophthalmol Inst, Oviedo, Spain

来源：

ACTA OPHTHALMOLOGICA | 2015年 / 93卷 / 08期

关键词：

autologous serum; cornea; dry eye; eye; ocular surface; plasma rich in growth factors; platelet-rich plasma; FACTORS PRGF-ENDORET; CORNEAL EPITHELIAL DEFECT; P-DERIVED PEPTIDE; DRY EYE; OCULAR SURFACE; TOPICAL FIBRONECTIN; PLATELET LYSATE; EYEDROPS; DROPS; TEARS;

D O I：

10.1111/aos.12710

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The use of blood derivatives represents an alternative therapeutic approach that is gaining interest in regenerative medicine due to its potential to stimulate and accelerate tissue healing. Autologous serum eye drops and platelet-enriched plasma eye drops are being used in the treatment of different ophthalmological disorders. In this review, we summarize the different blood-derived formulations used in the treatment and care of ocular surface disorders. The biological basis and use of autologous serum and plasma rich in growth factors are deeply evaluated as well as the challenges to be addressed in the future in this new generation of blood-derived therapies.

引用

页码：E605 / E614

页数：10

共 83 条

[1] Topical Treatment with a New Matrix Therapy Agent (RGTA) for the Treatment of Corneal Neurotrophic Ulcers [J].